Hexarelin

Hexarelin activates the ghrelin receptor (GHSR1a) on pituitary somatotrophs to stimulate GH release, and also acts at the hypothalamic level to suppress somatostatin and enhance GHRH secretion. Uniquely among GH secretagogues, hexarelin has demonstrated direct cardiac effects that appear to be mediated by a cardiac-specific GHSR subtype (possibly GHSR1b or a related receptor) rather than through GH elevation. In cardiac tissue, hexarelin activated PI3K/Akt and MAPK pathways, improving myocardial contractility and coronary blood flow. The desensitization phenomenon with chronic hexarelin use is thought to involve receptor downregulation and internalization at the pituitary level. Hexarelin also stimulates ACTH, cortisol, and prolactin through mechanisms similar to those described for GHRP-6 and GHRP-2.

Bisi et al. (1999) demonstrated that acute hexarelin administration improved cardiac output and ejection fraction in patients with severe heart failure, an effect that appeared independent of GH release. This raised interest in hexarelin for cardiovascular indications. However, Ghigo et al. (1997) showed that chronic hexarelin administration over 16 weeks led to significant attenuation of the GH response, with the desensitization being partial and dose-related. Arvat et al. (2000) reviewed hexarelin pharmacology and clinical data, noting cortisol and prolactin stimulation as additional limitations. No Phase 3 trials were conducted, and clinical development was discontinued. The cardiac findings remain scientifically interesting but have not been pursued therapeutically.

Hexarelin has no regulatory approval in any jurisdiction. Clinical development was discontinued and did not advance beyond Phase 2. It is classified as a research chemical. WADA prohibits hexarelin in sport under the GH-releasing factors category. It is available through grey-market peptide suppliers. Products are not manufactured under GMP conditions.

IGF-1 and GH levels at baseline and periodically to assess efficacy and detect tachyphylaxis. Morning cortisol and prolactin levels should be monitored with chronic use. If used for cardiac indications (off-label, investigational), echocardiographic monitoring may be appropriate. Fasting glucose and metabolic panel. Monitor for signs of GH response attenuation as a signal to discontinue or modify dosing strategy.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Hexarelin is supplied as a lyophilized powder, typically in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water. Refrigerate reconstituted solution at 2 to 8 degrees C and use within 2 to 4 weeks. Protect from heat, light, and repeated freeze-thaw cycles. Administer subcutaneously. Some users employ intermittent dosing schedules (e.g., 5 days on, 2 days off) in an attempt to mitigate tachyphylaxis, though this approach has not been validated in clinical studies.

1. 1

   RCT

   Hexarelin, a Synthetic Growth Hormone-Releasing Peptide, Acutely Improves Cardiac Performance in Heart Failure Patients

   Bisi G, Podio V, Valetto MR, et al. (1999). Journal of Clinical Endocrinology & Metabolism

   Key findings: Acute hexarelin administration improved cardiac output and ejection fraction in patients with severe heart failure, independent of GH release. Suggests direct cardiac effects via cardiac GHSR receptors.

   Limitations: Single-dose acute study. Small sample. Chronic cardiac effects not evaluated.

2. 2

   RCT

   Desensitization of the GH Response to Repeated Hexarelin Administration

   Ghigo E, Arvat E, Muccioli G, et al. (1997). Journal of Pediatric Endocrinology and Metabolism

   Key findings: Chronic hexarelin administration (over 16 weeks) led to significant attenuation of the GH response, indicating tachyphylaxis. The desensitization was partial and dose-related.

   Limitations: PK/PD study. Small sample. Mechanism of desensitization not fully elucidated.

3. 3

   review

   Hexarelin: Chemistry, Pharmacology, and Clinical Applications

   Arvat E, Broglio F, Ghigo E. (2000). Current Opinion in Investigational Drugs

   Key findings: Review of hexarelin covering its synthesis, receptor binding profile, GH-releasing activity, cardiac effects, and neuroendocrine actions. Notes cortisol and prolactin stimulation as limiting factors.

   Limitations: Review article. Clinical development did not advance beyond Phase 2.